PubHawk
June 2024 PMID 39028209

Semaglutide and obesity: beyond the nutritional and lifestyle intervention?

Livia Basile, Rossella Cannarella, Stefano Iuliano, Aldo E Calogero, Rosita A Condorelli, Emanuela A Greco, Antonio Aversa, Sandro LA Vignera

Download social card

Mentions

3
Peak: 1 in Jul 2024
across 2 sources since Jul 2024

Extended reach

462
potential audience

Total likes

23

Video views

239

Mentions per month

Jul 2024 – Mar 2025

Where it's discussed

  • YouTube2 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

Several discussions highlight the potential of Semaglutide as a breakthrough in obesity treatment, with comments like 'a promising option for non-diabetic patients' and 'more studies needed,' showing both optimism and critical awareness. The tone varies from enthusiastic to cautious, reflecting typical engaging medical discussions on new treatments.

AgreementModerate agreement

The discussions generally acknowledge the potential benefits of Semaglutide, with some users emphasizing its promising role in obesity treatment, reflected in supportive phrases and recognition of its efficacy.

InterestHigh interest

The discussions display high interest, with posters showing curiosity about the drug's effectiveness, delivery methods, and future research, frequently using words like 'excited' and 'intrigued.'

EngagementModerate engagement

Posts involve some depth, with participants referencing specific details about the drug's forms and implications, though mostly sharing opinions rather than detailed critiques.

ImpactModerate impact

Moderate impact is suggested, as posters consider the research significant within the context of obesity management but do not explicitly discuss broader societal or clinical policy implications.

Abstract in brief

  • Semaglutide is a glucagon-like peptide 1 receptor agonist that offers a new treatment option for obesity in non-diabetic individuals.
  • This review outlines its effectiveness in weight management, potential side effects, and reasons why some patients might stop using it.
  • The drug is available in two forms: a weekly subcutaneous injection and a daily oral pill, with the latter potentially being more appealing for patient adherence, but more studies are needed to confirm its efficacy.
Read the full abstract

Top posts

Most liked on X and Bluesky
Antonio Aversa
@DrAversa · X

Semaglutide and obesity: beyond the nutritional and lifestyle intervention? - https://t.co/MjQQu16O8W #ScholarAlerts

Jul 23, 2024 · 1 like · 224 followers View post →

All mentions

Antonio Aversa
@DrAversa · X

Semaglutide and obesity: beyond the nutritional and lifestyle intervention? - https://t.co/MjQQu16O8W #ScholarAlerts

Jul 23, 2024 · 1 like · 224 followers View post →